Cablevision’s support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research.

 

Clinical/Translational RFA's

2013 RFA CONCEPTS CLOSED

Early Detection and Risk Assessment in Pancreas Cancer

Apply for Grant

Pancreatic cancer patients seldom exhibit disease-specific symptoms until the cancer reaches an advanced stage, and tumors 1-2 cm in size often have already spread beyond the local area of the primary tumor. For these reasons, risk assessment and improved detection technologies are critically important. The Lustgarten Foundation therefore invites, collaborative or individual concept proposals for clinical or preclinical studies that investigate novel approaches for early detection of pre-metastatic pancreas cancer as well as strategies to better define "high-risk" patients. Early phase 0-1 clinical or preclinical proposals that are innovative and directly lead to human clinical trials are encouraged.

New Drug Delivery Approaches in Pancreas Cancer
Apply for Grant

The Lustgarten Foundation invites collaborative or individual concept proposals for preclinical and/or clinical trials that investigate novel approaches for improving the delivery of therapeutic agents to the neoplastic cells within pancreatic ductal adenocarcinomas at both the primary and metastatic sites. These proposals may include systemic and localized approaches that increase small molecule, biological (e.g., antibodies), and nucleic acid (e.g., genes, RNAi, ASO) delivery to the pancreatic tumor.  Proposals that describe methods to identify patients that are most likely to benefit from particular therapies because of their tumor architecture or metabolic features will also be considered.  Early phase 0-1 Clinical or preclinical proposals that are innovative and can lead to new types of therapeutic agents or treatment strategies are encouraged. Clinical proposals must include informative correlative studies to assess improvements in drug delivery in vivo.

Novel Imaging Technologies in Pancreas Cancer
Apply for Grant

The Lustgarten Foundation invites collaborative or individual concept proposals for preclinical and/or clinical trials that develop and test novel imaging modalities for early diagnosis of pancreatic ductal adenocarcinoma or improved intraoperative detection of cancer. Early phase 0-1 clinical or preclinical proposals that are innovative and directly lead to human clinical trials are encouraged as well as phase 2 proposals that have shown success in phase 0-1.

Early detection proposals may involve surveillance of high-risk populations (including carriers of inherited mutations, patients with ductal abnormalities such as IPMN, or mucinous cystic neoplasms) or may be directed at the general population. Proposals directed at defining the significance of pancreatic duct strictures or risk stratification of pancreatic cysts are encouraged, as well as proposals that define imaging correlates in patients with preclinical biomarkers. 


Novel Therapeutic Agents in Pancreas Cancer
Apply for Grant

The Lustgarten Foundation invites collaborative or individual concept proposals utilizing preclinical and/or clinical trials to investigate novel agents to improve the treatment and care of patients with pancreatic ductal adenocarcinoma. The agents proposed may be already approved for another indication but not yet studied in pancreatic cancers; novel new agents; or combinations thereof.  These may include small molecule, biological (eg antibodies), and nucleic acids (eg. genes, RNAi, ASO) and may be aimed at increasing radio-sensitization, modulating immune responses, enhancing palliative care, or other areas to improve treatment and care.  Early phase 0-1 clinical or preclinical proposals that are innovative and can lead to new therapeutics or treatment strategies are encouraged. Clinical proposals must include significantly informative correlative studies to show mechanism as well as evidence of clinical activity. 

Correlative Studies Awards Program
Apply for Grant

The Lustgarten Foundation is seeking applications for Correlative Studies associated with funded clinical trials for pancreatic cancer.

Download the 2013 Grant Poster

 

2012 Annual Report

Learn more about our commitment in the fight against pancreatic cancer.

Join Now

Lustgarten Facebook Lustgarten Twitter Lustgarten YouTube channel

The Lustgarten Foundation
1111 Stewart Avenue, Bethpage, New York 11714
Toll Free: 1-866-789-1000 P: 516-803-2304 F: 516-803-2303

©2009 Lustgarten Foundation - 501(c)3 - CharityNavigator: 4 Stars